Cellceutix Press Release Title List: 08/20/15 C
Post# of 72446
Posted On: 08/22/2015 3:28:46 PM
Cellceutix Press Release Title List:
08/20/15 Cellceutix’s Clinical Trial of Anti-Cancer Agent Kevetrin Meeting Its Goals, Approaching End of Trial
08/11/15 Cellceutix’s Kevetrin and Thymoma — a Rare Cancer
08/10/15 Cellceutix: Thank You
08/07/15 Cellceutix Provides Insights to its Four Clinical Trials for the Treatment of ABSSSI (Completed Phase 2), Anti-Cancer (Phase 1), Psoriasis (Phase 2), and Oral Mucositis in Head and Neck Cancer Patients (Phase 2)
08/06/15 Cellceutix Commences Phase 2 Trial of Prurisol as New Treatment for Psoriasis
08/03/15 Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
07/20/15 Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
07/15/15 Cellceutix’s Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
06/08/15 Cellceutix Provides Update on Uplist Application
06/03/15 Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
06/01/15 Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
05/28/15 Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
05/25/15 Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
05/22/15 IRB Approves Additional Enrollment in Cellceutix’s Clinical Trial of New Cancer Drug Candidate for Solid Tumors
05/13/15 Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
04/27/15 Cellceutix Selects Independent Directors and Committee Members
04/21/15 Cellceutix Provides Corporate Update
04/13/15 Cellceutix PIND Meeting Scheduled with FDA for Hidradenitis Suppurativa
04/01/15 Cellceutix Enters Into a $30 Million Common Stock Purchase Agreement
03/24/15 Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
03/16/15 Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
03/02/15 Cellceutix To Expand its Skin Product Pipeline
01/27/15 Cellceutix Enthusiastic About Proposed Budget Increase to $1.2 Billion to Fight Drug-Resistance Bacteria
01/26/15 Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
01/22/15 Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
01/20/15 Cellceutix Reports Spleen Lesion ‘Disappears’ in Patient with Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
01/11/15 Cellceutix Invites All to Attend Company’s Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
01/05/15 Cellceutix Releases Confidence Interval Statistics Showing Clinical Success Rates for Brilacidin in Treatment of ABSSSI
12/29/14 Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer
12/22/14 Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted
12/10/14 Cellceutix: Prurisol™ for Psoriasis — FDA Agrees That Phase 2 Study May Begin
12/08/14 Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
11/24/14 Cellceutix: December to Be Momentous Month in Company’s History
11/10/14 Patient Enrollment in Cellceutix Phase 01/01/00 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 07/06/05
10/31/14 Cellceutix’s New Chief Operating Officer Dr. James Alexander Addresses Shareholders
10/23/14 Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
10/13/14 Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site For Phase 2 Clinical Trial Of New Treatment For Oral Mucositis
09/28/14 Cellceutix Provides Update to Shareholders
09/19/14 Cellceutix to President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat to Public Health
09/09/14 Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
09/05/14 Cellceutix to Present at Rodman & Renshaw’s 16th Annual Global Investment Conference
09/02/14 Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
08/19/14 Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
08/11/14 Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
08/07/14 Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial
08/04/14 Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected this Month
07/14/14 Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers
07/07/14 Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs)
06/23/14 Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
06/16/14 Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
06/02/14 Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
05/27/14 Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities
05/19/14 Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market
05/12/14 Cellceutix Confident in Its Formidable Antibiotic Arsenal
05/05/14 Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis
04/14/14 Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae
04/01/14 Cellceutix Comments On Positive FDA Advisory Vote For Dalbavancin And Tedizolid
03/31/14 Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
03/24/14 Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
03/21/14 Cellceutix to Initiate Psoriasis Clinical Trial
03/19/14 Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors
03/10/14 Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial
03/05/14 Cellceutix Expands to Gram-Negative Bacterial Infections
02/25/14 Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
02/24/14 Cellceutix Selects Dr. Reddy’s Laboratories For Formulation of Brilacidin for Ophthalmic and Otitis Infections
02/18/14 Cellceutix Submits Investigational New Drug Application (IND) for Clinical Trial of New Anti-Psoriasis Drug, Enrollment Underway in Phase 2b Clinical Trials of Brilacidin
02/03/14 Cellceutix Files with FDA for Phase 2b Clinical Trial of Novel Antibiotic Brilacidin; Enrollment of Patients Expected to Start Mid-February
01/21/14 Cellceutix Sees Increased Valuation Potential for its Novel Antibiotic Brilacidin
01/15/14 Cellceutix Provides Updates on Clinical Trials and Developments of its Anti-Cancer, Anti-Psoriasis, and Antibiotic Compounds
01/13/14 Cellceutix Corporation to Present at Biotech Showcase 2014
01/06/14 Cellceutix Submits Application to Institutional Review Board to Commence Clinical Trials of Anti-Psoriasis Drug Prurisol
12/20/13 Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
12/15/13 Cellceutix Submits Application for IRB Review to Commence Phase 2b Clinical Trial of Novel Antibiotic Brilacidin
12/09/13 Cellceutix Updates on Current Status of Programs
11/18/13 Cellceutix Identifies Drug Candidates for Gram-Negative and Candida Fungal Infections
11/04/13 Cellceutix to Pursue Significant Conjunctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin
10/29/13 Cellceutix Enters Into New $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
10/21/13 Cellceutix Structures for Significant Growth in Upcoming Year
10/14/13 Cellceutix Drug Brilacidin™ May Be The Key Antibiotic on the Horizon for Serious Skin Infections; Plans to Start Phase 2b Study in January 2014
10/10/13 Cellceutix Antibiotic Brilacidin Chosen by Elsevier as “Top Project to Watch” in Infectious Disease
10/02/13 Cellceutix Completes Final Study to File IND Application for New Psoriasis Drug Prurisol
09/24/13 Cellceutix Plans Phase 2b Trial of New Antibiotic, Reports Fifth Cohort Complete in Novel Cancer Drug Clinical Trial
09/15/13 Cellceutix Completes Acquisition Of Polymedix Assets, Immediately Plans Brilacidin™ Phase 2b Clinical Trial For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) and Phase 2 Clinical Trial For Oral Mucositis
09/09/13 Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
08/12/13 Cellceutix Clinical Study on its Anti-Psoriasis Drug Prurisol™ to Commence
06/26/13 Cellceutix Signs Material Transfer Agreement for Research of Kevetrin in Lymphoma and Multiple Myeloma Cancers With Major Cancer Center
06/14/13 Cellceutix Reports Kevetrin™ Dosing Increases and Prurisol™ Anti-Psoriasis Drug Stability Tests Underway
06/03/13 Cellceutix Presents Poster at ASCO on its Clinical Trial of Anti-Cancer Drug Kevetrin
05/28/13 Cellceutix to Present Poster on Novel Anti-Cancer Drug at Annual ASCO Meeting
04/05/13 Coach Jim Boeheim Putting Up His Best Defense Against Michigan…and Cancer
03/29/13 Cellceutix Selected for Poster Presentation on Kevetrin at 2013 ASCO Meeting
03/08/13 Cellceutix Plans for Future Trials Aimed at the Latest Initiatives of ‘Breakthrough’ Designation by the Food and Drug Administration
03/04/13 Cellceutix Signs with Leading Cancer Center For Licensing New Drug
02/22/13 Cellceutix Reports on Kevetrin Clinical Trials and Prurisol Manufacturing
02/01/13 Cellceutix Abstract for Annual American Society of Clinical Oncology Meeting
01/24/13 Cellceutix Reports In Vivo Tumor Shrinkage in Renal Cancer
01/06/13 Cellceutix Announces A Study Planned At The University Of Bologna Titled “A Multi-Center, Open-Label, Phase Ib Study Of Kevetrin With Cytarabine In Patients With Acute Myelogenous Leukemia (AML)” ; U.S. Patent Issued for Kevetrin, Cellceutix’s p53 Anti-Cancer Compound
12/30/12 Cellceutix CEO Discusses Corporate Developments in 2012 And Plans For 2013
12/23/12 Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
12/14/12 Cellceutix Announces Kevetrin Dosing Levels Increased as Clinical Trials Advance
12/09/12 Cellceutix Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
11/30/12 Cellceutix Anti-Cancer Drug Kevetrin Completes Dosing Cycle, Ready for Next Cohort
11/09/12 Cellceutix Signs Agreement for Clinical Trial in Europe on New Psoriasis Drug
11/07/12 Cellceutix Hits Major Milestone in Company History; Dosing Underway for New Cancer Drug at Leading Hospitals
10/29/12 First Patients Recruited and Enrolled in Cellceutix Clinical Trial of Novel Anti-Cancer Drug Kevetrin
10/19/12 Clinical Trials for Cellceutix Novel Anti-Cancer Drug Now Active at Leading Hospitals
10/05/12 Clinical Trials Going Active for Cellceutix Anti-Cancer Drug Kevetrin
09/21/12 Cellceutix to Commence Clinical Trials for its Novel Anti-Cancer Drug Kevetrin
09/07/12 Cellceutix Plans for European Funded Leukemia Phase 1 Trial
08/30/12 Cellceutix Anti-Psoriasis Drug Advances Toward Phase 2 Clinical Trials With Selection of Dr. Reddy’s Laboratories For Manufacturing
08/06/12 Cellceutix Reports Its Very Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber for Start of Clinical Trials
07/23/12 Cellceutix Cancer Trial Enrollment Planned for August 2012
07/16/12 Cellceutix Meets Manufacturers to Synthesize Psoriasis Drug Candidate for Clinical Trials; Site Initiation Visit for Clinical Trials of Kevetrin to Happen This Week
07/09/12 Cellceutix Sets for Cancer Patient Enrollment in Clinical Trial of Pioneering p53 Cancer Drug
06/26/12 Cellceutix Novel Anti-Cancer Drug Kevetrin™ Receives IRB and SRC Approvals for Clinical Trials at Harvard’s Dana-Farber Cancer Institute
06/22/12 Cellceutix Approved by FDA to Proceed With Clinical Trials on Novel Cancer Drug
06/18/12 Cellceutix Preparing for Phase 2 Clinical Trials With New Psoriasis Drug
06/13/12 Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable Approach for Its Psoriasis Drug
05/30/12 Cellceutix Adds Brain Cancer to Growing List of Indications for Its Novel Cancer Drug
05/21/12 Cellceutix Files Amended IND With FDA for Its Novel p53 “Guardian Angel” Anti-Cancer Drug
05/14/12 Cellceutix Arranges $1 Million Financing for Clinical Trials of New Cancer Drug; IND Filing Imminent
05/07/12 Syracuse Basketball Icon Jim Boeheim Joins Cellceutix to Fight Cancer
04/16/12 FDA Schedules Meeting With Cellceutix on New Psoriasis Drug
04/04/12 Cellceutix Novel Anti-Cancer Compound Kevetrin™ Presented at American Association for Cancer Research Annual Meeting
03/19/12 Cellceutix Enters Into a Collaborative Agreement With Beth Israel Deaconess Medical Center for Pro-Apoptotic Function of p53 in Melanoma and Renal Cell Carcinoma
03/12/12 Cellceutix Files Pre-IND Documentation to FDA for New Psoriasis Drug
02/27/12 Cellceutix ‘Back in the Game’ With cGMP Manufacturing Completed on New Cancer Drug
01/23/12 Cellceutix Featured on Cover of Prominent Business Journal
01/17/12 Cellceutix Anti-Cancer Drug Shown to Regulate HDAC2, a Major Therapeutic Target for Treatment of a Broad Range of Cancers
01/03/12 Cellceutix Ushers in 2012 With Plans for Clinical Trials for Anti-Cancer and Psoriasis Drugs
12/13/11 Cellceutix Provides Updates on IND for Cancer Drug, Initiates Collaborative Agreement With Pioneer Valley Life Sciences Institute for Mitochondrial Research
11/28/11 Dr. Paul Marks Joins Cellceutix Scientific Advisory Board; Cellceutix Files Worldwide Patents to Protect Kevetrin™
11/07/11 Cellceutix Files Investigational New Drug Application (IND) With FDA, Clinical Trials Planned at Dana-Farber/Harvard Cancer Center
10/25/11 Cellceutix to File Investigational New Drug Application for Novel p53 Anti-Cancer Drug
10/17/11 Cellceutix Confident as Cancer Compound Shows Activity in All Cancers Tested
10/10/11 Prostate Cancer Joins Growing List of Cancers That Succumb to Cellceutix Corporation’s Potent Anti-Cancer Drug
10/03/11 Cellceutix’s Drug Discovery Is a Major Leap Forward in the Fight Against Cancer
09/26/11 Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug
09/21/11 Cellceutix Signs Lab Services Research Support Agreement With Dana Farber/Partners CancerCare, Inc.
08/01/11 With Contracts and IND Application in Hand, Cellceutix Nears Clinical Trials for New Cancer Drug
07/19/11 Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial
06/27/11 Cellceutix Provides Updates on Kevetrin™, Cellceutix’s Novel Anti-Cancer Therapy
06/20/11 Cellceutix’s Kevetrin™ Slows Pancreatic Cancer Tumor Growth by 94%; Protocol Towards Clinical Trials Nearing End
06/06/11 Vendor Showcases Kevetrin™, Cellceutix’s Anti-Cancer Drug at American Society for Mass Spectrometry Meeting
05/23/11 Cellceutix CEO States “Full Speed Ahead”
05/16/11 Cellceutix Announces Kevetrin™ in Combination With Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study
05/09/11 Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site
05/03/11 Insight Into Cellceutix Corporation’s Breakthrough Cancer Compound
04/25/11 Cellceutix Cancer Drug Trumps Competitors
02/28/11 Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the “Guardian Angel of the Human Genome”
02/14/11 Cellceutix Announces Settlement With Former CEO
11/09/10 Cellceutix Announces Departure of George W. Evans as CEO
11/04/10 Cellceutix Receives Federal Grants for Each of Its Active Research Programs; Total Exceeds $730,000
10/28/10 Cellceutix Completes Final Toxicity Study for Its Cancer Compound; United States Food and Drug Administration IND Application Underway
09/28/10 Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment of Resistant Lung and Breast Cancers
08/24/10 Cellceutix Closing in on Human Trials with Kevetrin™ for Drug-Resistant Cancers as the Company Reports Progress on Toxicity Studies
07/26/10 Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound
07/07/10 Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to Filing Investigational New Drug (IND) Application
06/23/10 Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain
06/21/10 Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells
06/14/10 New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes; Chief Scientific Officer Sees Potential for Company to Emerge as Industry Leader as Pharmas Strive for Revolutionary Autism Treatments
06/07/10 Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound
06/03/10 Cellceutix CFO Discusses Autism Drug, Kevetrin™ and Company Progressions With CEOCFO Interviews and News
05/24/10 Cellceutix Signs Agreements for Kevetrin™ Phase 1 Support; Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers
05/18/10 Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer Compound
05/12/10 Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound; Pfizer and Novartis Announcements Indicate Interest in Autism by Major Companies
04/21/10 Cellceutix Presents Poster Session at AACR; Important New Data on Kevetrin™ in Resistant Lung Cancer Model Show Dose Response; No Tumor Cell Resistance With Second Cycle
08/20/15 Cellceutix’s Clinical Trial of Anti-Cancer Agent Kevetrin Meeting Its Goals, Approaching End of Trial
08/11/15 Cellceutix’s Kevetrin and Thymoma — a Rare Cancer
08/10/15 Cellceutix: Thank You
08/07/15 Cellceutix Provides Insights to its Four Clinical Trials for the Treatment of ABSSSI (Completed Phase 2), Anti-Cancer (Phase 1), Psoriasis (Phase 2), and Oral Mucositis in Head and Neck Cancer Patients (Phase 2)
08/06/15 Cellceutix Commences Phase 2 Trial of Prurisol as New Treatment for Psoriasis
08/03/15 Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
07/20/15 Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
07/15/15 Cellceutix’s Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
06/08/15 Cellceutix Provides Update on Uplist Application
06/03/15 Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
06/01/15 Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
05/28/15 Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
05/25/15 Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
05/22/15 IRB Approves Additional Enrollment in Cellceutix’s Clinical Trial of New Cancer Drug Candidate for Solid Tumors
05/13/15 Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
04/27/15 Cellceutix Selects Independent Directors and Committee Members
04/21/15 Cellceutix Provides Corporate Update
04/13/15 Cellceutix PIND Meeting Scheduled with FDA for Hidradenitis Suppurativa
04/01/15 Cellceutix Enters Into a $30 Million Common Stock Purchase Agreement
03/24/15 Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
03/16/15 Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
03/02/15 Cellceutix To Expand its Skin Product Pipeline
01/27/15 Cellceutix Enthusiastic About Proposed Budget Increase to $1.2 Billion to Fight Drug-Resistance Bacteria
01/26/15 Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
01/22/15 Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
01/20/15 Cellceutix Reports Spleen Lesion ‘Disappears’ in Patient with Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
01/11/15 Cellceutix Invites All to Attend Company’s Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
01/05/15 Cellceutix Releases Confidence Interval Statistics Showing Clinical Success Rates for Brilacidin in Treatment of ABSSSI
12/29/14 Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer
12/22/14 Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted
12/10/14 Cellceutix: Prurisol™ for Psoriasis — FDA Agrees That Phase 2 Study May Begin
12/08/14 Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
11/24/14 Cellceutix: December to Be Momentous Month in Company’s History
11/10/14 Patient Enrollment in Cellceutix Phase 01/01/00 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 07/06/05
10/31/14 Cellceutix’s New Chief Operating Officer Dr. James Alexander Addresses Shareholders
10/23/14 Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
10/13/14 Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site For Phase 2 Clinical Trial Of New Treatment For Oral Mucositis
09/28/14 Cellceutix Provides Update to Shareholders
09/19/14 Cellceutix to President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat to Public Health
09/09/14 Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
09/05/14 Cellceutix to Present at Rodman & Renshaw’s 16th Annual Global Investment Conference
09/02/14 Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
08/19/14 Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
08/11/14 Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
08/07/14 Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial
08/04/14 Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected this Month
07/14/14 Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers
07/07/14 Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs)
06/23/14 Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
06/16/14 Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
06/02/14 Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
05/27/14 Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities
05/19/14 Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market
05/12/14 Cellceutix Confident in Its Formidable Antibiotic Arsenal
05/05/14 Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis
04/14/14 Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae
04/01/14 Cellceutix Comments On Positive FDA Advisory Vote For Dalbavancin And Tedizolid
03/31/14 Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
03/24/14 Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
03/21/14 Cellceutix to Initiate Psoriasis Clinical Trial
03/19/14 Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors
03/10/14 Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial
03/05/14 Cellceutix Expands to Gram-Negative Bacterial Infections
02/25/14 Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
02/24/14 Cellceutix Selects Dr. Reddy’s Laboratories For Formulation of Brilacidin for Ophthalmic and Otitis Infections
02/18/14 Cellceutix Submits Investigational New Drug Application (IND) for Clinical Trial of New Anti-Psoriasis Drug, Enrollment Underway in Phase 2b Clinical Trials of Brilacidin
02/03/14 Cellceutix Files with FDA for Phase 2b Clinical Trial of Novel Antibiotic Brilacidin; Enrollment of Patients Expected to Start Mid-February
01/21/14 Cellceutix Sees Increased Valuation Potential for its Novel Antibiotic Brilacidin
01/15/14 Cellceutix Provides Updates on Clinical Trials and Developments of its Anti-Cancer, Anti-Psoriasis, and Antibiotic Compounds
01/13/14 Cellceutix Corporation to Present at Biotech Showcase 2014
01/06/14 Cellceutix Submits Application to Institutional Review Board to Commence Clinical Trials of Anti-Psoriasis Drug Prurisol
12/20/13 Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
12/15/13 Cellceutix Submits Application for IRB Review to Commence Phase 2b Clinical Trial of Novel Antibiotic Brilacidin
12/09/13 Cellceutix Updates on Current Status of Programs
11/18/13 Cellceutix Identifies Drug Candidates for Gram-Negative and Candida Fungal Infections
11/04/13 Cellceutix to Pursue Significant Conjunctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin
10/29/13 Cellceutix Enters Into New $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
10/21/13 Cellceutix Structures for Significant Growth in Upcoming Year
10/14/13 Cellceutix Drug Brilacidin™ May Be The Key Antibiotic on the Horizon for Serious Skin Infections; Plans to Start Phase 2b Study in January 2014
10/10/13 Cellceutix Antibiotic Brilacidin Chosen by Elsevier as “Top Project to Watch” in Infectious Disease
10/02/13 Cellceutix Completes Final Study to File IND Application for New Psoriasis Drug Prurisol
09/24/13 Cellceutix Plans Phase 2b Trial of New Antibiotic, Reports Fifth Cohort Complete in Novel Cancer Drug Clinical Trial
09/15/13 Cellceutix Completes Acquisition Of Polymedix Assets, Immediately Plans Brilacidin™ Phase 2b Clinical Trial For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) and Phase 2 Clinical Trial For Oral Mucositis
09/09/13 Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
08/12/13 Cellceutix Clinical Study on its Anti-Psoriasis Drug Prurisol™ to Commence
06/26/13 Cellceutix Signs Material Transfer Agreement for Research of Kevetrin in Lymphoma and Multiple Myeloma Cancers With Major Cancer Center
06/14/13 Cellceutix Reports Kevetrin™ Dosing Increases and Prurisol™ Anti-Psoriasis Drug Stability Tests Underway
06/03/13 Cellceutix Presents Poster at ASCO on its Clinical Trial of Anti-Cancer Drug Kevetrin
05/28/13 Cellceutix to Present Poster on Novel Anti-Cancer Drug at Annual ASCO Meeting
04/05/13 Coach Jim Boeheim Putting Up His Best Defense Against Michigan…and Cancer
03/29/13 Cellceutix Selected for Poster Presentation on Kevetrin at 2013 ASCO Meeting
03/08/13 Cellceutix Plans for Future Trials Aimed at the Latest Initiatives of ‘Breakthrough’ Designation by the Food and Drug Administration
03/04/13 Cellceutix Signs with Leading Cancer Center For Licensing New Drug
02/22/13 Cellceutix Reports on Kevetrin Clinical Trials and Prurisol Manufacturing
02/01/13 Cellceutix Abstract for Annual American Society of Clinical Oncology Meeting
01/24/13 Cellceutix Reports In Vivo Tumor Shrinkage in Renal Cancer
01/06/13 Cellceutix Announces A Study Planned At The University Of Bologna Titled “A Multi-Center, Open-Label, Phase Ib Study Of Kevetrin With Cytarabine In Patients With Acute Myelogenous Leukemia (AML)” ; U.S. Patent Issued for Kevetrin, Cellceutix’s p53 Anti-Cancer Compound
12/30/12 Cellceutix CEO Discusses Corporate Developments in 2012 And Plans For 2013
12/23/12 Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
12/14/12 Cellceutix Announces Kevetrin Dosing Levels Increased as Clinical Trials Advance
12/09/12 Cellceutix Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
11/30/12 Cellceutix Anti-Cancer Drug Kevetrin Completes Dosing Cycle, Ready for Next Cohort
11/09/12 Cellceutix Signs Agreement for Clinical Trial in Europe on New Psoriasis Drug
11/07/12 Cellceutix Hits Major Milestone in Company History; Dosing Underway for New Cancer Drug at Leading Hospitals
10/29/12 First Patients Recruited and Enrolled in Cellceutix Clinical Trial of Novel Anti-Cancer Drug Kevetrin
10/19/12 Clinical Trials for Cellceutix Novel Anti-Cancer Drug Now Active at Leading Hospitals
10/05/12 Clinical Trials Going Active for Cellceutix Anti-Cancer Drug Kevetrin
09/21/12 Cellceutix to Commence Clinical Trials for its Novel Anti-Cancer Drug Kevetrin
09/07/12 Cellceutix Plans for European Funded Leukemia Phase 1 Trial
08/30/12 Cellceutix Anti-Psoriasis Drug Advances Toward Phase 2 Clinical Trials With Selection of Dr. Reddy’s Laboratories For Manufacturing
08/06/12 Cellceutix Reports Its Very Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber for Start of Clinical Trials
07/23/12 Cellceutix Cancer Trial Enrollment Planned for August 2012
07/16/12 Cellceutix Meets Manufacturers to Synthesize Psoriasis Drug Candidate for Clinical Trials; Site Initiation Visit for Clinical Trials of Kevetrin to Happen This Week
07/09/12 Cellceutix Sets for Cancer Patient Enrollment in Clinical Trial of Pioneering p53 Cancer Drug
06/26/12 Cellceutix Novel Anti-Cancer Drug Kevetrin™ Receives IRB and SRC Approvals for Clinical Trials at Harvard’s Dana-Farber Cancer Institute
06/22/12 Cellceutix Approved by FDA to Proceed With Clinical Trials on Novel Cancer Drug
06/18/12 Cellceutix Preparing for Phase 2 Clinical Trials With New Psoriasis Drug
06/13/12 Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable Approach for Its Psoriasis Drug
05/30/12 Cellceutix Adds Brain Cancer to Growing List of Indications for Its Novel Cancer Drug
05/21/12 Cellceutix Files Amended IND With FDA for Its Novel p53 “Guardian Angel” Anti-Cancer Drug
05/14/12 Cellceutix Arranges $1 Million Financing for Clinical Trials of New Cancer Drug; IND Filing Imminent
05/07/12 Syracuse Basketball Icon Jim Boeheim Joins Cellceutix to Fight Cancer
04/16/12 FDA Schedules Meeting With Cellceutix on New Psoriasis Drug
04/04/12 Cellceutix Novel Anti-Cancer Compound Kevetrin™ Presented at American Association for Cancer Research Annual Meeting
03/19/12 Cellceutix Enters Into a Collaborative Agreement With Beth Israel Deaconess Medical Center for Pro-Apoptotic Function of p53 in Melanoma and Renal Cell Carcinoma
03/12/12 Cellceutix Files Pre-IND Documentation to FDA for New Psoriasis Drug
02/27/12 Cellceutix ‘Back in the Game’ With cGMP Manufacturing Completed on New Cancer Drug
01/23/12 Cellceutix Featured on Cover of Prominent Business Journal
01/17/12 Cellceutix Anti-Cancer Drug Shown to Regulate HDAC2, a Major Therapeutic Target for Treatment of a Broad Range of Cancers
01/03/12 Cellceutix Ushers in 2012 With Plans for Clinical Trials for Anti-Cancer and Psoriasis Drugs
12/13/11 Cellceutix Provides Updates on IND for Cancer Drug, Initiates Collaborative Agreement With Pioneer Valley Life Sciences Institute for Mitochondrial Research
11/28/11 Dr. Paul Marks Joins Cellceutix Scientific Advisory Board; Cellceutix Files Worldwide Patents to Protect Kevetrin™
11/07/11 Cellceutix Files Investigational New Drug Application (IND) With FDA, Clinical Trials Planned at Dana-Farber/Harvard Cancer Center
10/25/11 Cellceutix to File Investigational New Drug Application for Novel p53 Anti-Cancer Drug
10/17/11 Cellceutix Confident as Cancer Compound Shows Activity in All Cancers Tested
10/10/11 Prostate Cancer Joins Growing List of Cancers That Succumb to Cellceutix Corporation’s Potent Anti-Cancer Drug
10/03/11 Cellceutix’s Drug Discovery Is a Major Leap Forward in the Fight Against Cancer
09/26/11 Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug
09/21/11 Cellceutix Signs Lab Services Research Support Agreement With Dana Farber/Partners CancerCare, Inc.
08/01/11 With Contracts and IND Application in Hand, Cellceutix Nears Clinical Trials for New Cancer Drug
07/19/11 Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial
06/27/11 Cellceutix Provides Updates on Kevetrin™, Cellceutix’s Novel Anti-Cancer Therapy
06/20/11 Cellceutix’s Kevetrin™ Slows Pancreatic Cancer Tumor Growth by 94%; Protocol Towards Clinical Trials Nearing End
06/06/11 Vendor Showcases Kevetrin™, Cellceutix’s Anti-Cancer Drug at American Society for Mass Spectrometry Meeting
05/23/11 Cellceutix CEO States “Full Speed Ahead”
05/16/11 Cellceutix Announces Kevetrin™ in Combination With Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study
05/09/11 Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site
05/03/11 Insight Into Cellceutix Corporation’s Breakthrough Cancer Compound
04/25/11 Cellceutix Cancer Drug Trumps Competitors
02/28/11 Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the “Guardian Angel of the Human Genome”
02/14/11 Cellceutix Announces Settlement With Former CEO
11/09/10 Cellceutix Announces Departure of George W. Evans as CEO
11/04/10 Cellceutix Receives Federal Grants for Each of Its Active Research Programs; Total Exceeds $730,000
10/28/10 Cellceutix Completes Final Toxicity Study for Its Cancer Compound; United States Food and Drug Administration IND Application Underway
09/28/10 Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment of Resistant Lung and Breast Cancers
08/24/10 Cellceutix Closing in on Human Trials with Kevetrin™ for Drug-Resistant Cancers as the Company Reports Progress on Toxicity Studies
07/26/10 Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound
07/07/10 Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to Filing Investigational New Drug (IND) Application
06/23/10 Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain
06/21/10 Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells
06/14/10 New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes; Chief Scientific Officer Sees Potential for Company to Emerge as Industry Leader as Pharmas Strive for Revolutionary Autism Treatments
06/07/10 Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound
06/03/10 Cellceutix CFO Discusses Autism Drug, Kevetrin™ and Company Progressions With CEOCFO Interviews and News
05/24/10 Cellceutix Signs Agreements for Kevetrin™ Phase 1 Support; Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers
05/18/10 Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer Compound
05/12/10 Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound; Pfizer and Novartis Announcements Indicate Interest in Autism by Major Companies
04/21/10 Cellceutix Presents Poster Session at AACR; Important New Data on Kevetrin™ in Resistant Lung Cancer Model Show Dose Response; No Tumor Cell Resistance With Second Cycle
(0)
(0)